InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
T+90 hit rate
53%
T+90 mean return
+5.8%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by M. Pykett, Director. Officer active across 1 company, notably Pharming Group N.V.. In total, 16 reports have been logged. History available since 24 March 2021. The latest transaction was filed on 10 June 2025 (Purchase). Regulator: AFM. The full history is openly available.
Declarations16 total
31,400 shares0Gewoon aandeelAFM:176245
Ideal exit: 7 Mar 2026 (T+270)
8,487 shares0Gewoon aandeelAFM:165348
Ideal exit: 28 Jul 2025 (T+270)
8,487 shares0Gewoon aandeelAFM:161781
Ideal exit: 28 Apr 2025 (T+270)
9,553 shares0Gewoon aandeelAFM:159038
Ideal exit: 23 Feb 2025 (T+270)
7,419 shares0Gewoon aandeelAFM:155755
Ideal exit: 10 Dec 2024 (T+270)
7,234 shares0Gewoon aandeelAFM:149885
Ideal exit: 27 Jul 2024 (T+270)
7,234 shares0Gewoon aandeelAFM:146141
Ideal exit: 29 Apr 2024 (T+270)
7,446 shares0Gewoon aandeelAFM:143211
Ideal exit: 18 Feb 2024 (T+270)
7,022 shares0Gewoon aandeelAFM:138775
Ideal exit: 16 Dec 2023 (T+270)
9,760 shares@ €0.9411.8% of flowGewoon aandeelAFM:132723
Ideal exit: 24 Jul 2023 (T+270)
9,760 shares@ €0.76859.6% of flowGewoon aandeelAFM:128013
Ideal exit: 1 May 2023 (T+270)
9,300 shares@ €0.76859.2% of flowGewoon aandeelAFM:125088
Ideal exit: 19 Feb 2023 (T+270)
10,220 shares@ €0.73389.6% of flowGewoon aandeelAFM:122172
Ideal exit: 19 Dec 2022 (T+270)
7,241 shares@ €1.03589.6% of flowGewoon aandeelAFM:116792
Ideal exit: 25 Jul 2022 (T+270)
14,909 shares@ €1.035819.8% of flowGewoon aandeelAFM:114817
Ideal exit: 2 May 2022 (T+270)
21,997 shares@ €1.07130.3% of flowGewoon aandeelAFM:108690
Ideal exit: 19 Dec 2021 (T+270)
16 of 16 declarations
About M. Pykett
M. Pykett is a board member at Pharming Group N.V. He plays an active role in the governance of the company, which focuses on biopharmaceutical solutions. His expertise in the sector is crucial for Pharming's strategic decisions.
